MedKoo Cat#: 328009 | Name: Nexopamil

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nexopamil, also known as LU-49938, a calcium channel antagonist and serotonin 2A receptor antagonist potentially for the treatment of angina pectoris. Nexopamil inhibits both 5-HT-induced mesangial cell contraction and proliferation by blocking 5-HT2 receptors and the voltage-operated Ca2+ channels.

Chemical Structure

Nexopamil
CAS#136033-49-3

Theoretical Analysis

MedKoo Cat#: 328009

Name: Nexopamil

CAS#: 136033-49-3

Chemical Formula: C24H40N2O3

Exact Mass: 404.3039

Molecular Weight: 404.60

Elemental Analysis: C, 71.25; H, 9.97; N, 6.92; O, 11.86

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Nexopamil; LU-49938; LU 49938; LU49938.
IUPAC/Chemical Name
(2S)-5-(Hexylmethylamino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile
InChi Key
SKDZEFVVFACNLS-DEOSSOPVSA-N
InChi Code
InChI=1S/C24H40N2O3/c1-8-9-10-11-14-26(4)15-12-13-24(18-25,19(2)3)20-16-21(27-5)23(29-7)22(17-20)28-6/h16-17,19H,8-15H2,1-7H3/t24-/m0/s1
SMILES Code
N#C[C@](C1=CC(OC)=C(OC)C(OC)=C1)(C(C)C)CCCN(CCCCCC)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 404.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Nearing BD, Hutter JJ, Verrier RL. Potent antifibrillatory effect of combined blockade of calcium channels and 5-HT2 receptors with nexopamil during myocardial ischemia and reperfusion in dogs: comparison to diltiazem. J Cardiovasc Pharmacol. 1996 Jun;27(6):777-87. PubMed PMID: 8761843. 2: Park SJ, Lee JJ, Kirchengast M, Boulanger CM, Vanhoutte PM. The combined 5-HT2 receptor and calcium channel inhibitor LU49938 restores endothelium dependent responses in the regenerated endothelium of the porcine coronary artery. Cardiovasc Res. 1995 Jan;29(1):95-101. PubMed PMID: 7895245. 3: Montero A, Rodríguez-López A, Reverte M, López-Novoa JM. The effect of LU-49938 (nexopamil) on the activation by serotonin of mesangial cells. Fundam Clin Pharmacol. 1995;9(2):175-80. PubMed PMID: 7628831. 4: Park SJ, Boulanger CM, Kirchengast M, Vanhoutte PM. Effects of the combined 5-hydroxytryptamine2 receptor and Ca2+ channel antagonist LU49938 on the responsiveness of isolated porcine coronary arteries with and without endothelium. J Cardiovasc Pharmacol. 1994 Sep;24(3):517-22. PubMed PMID: 7528308. 5: Hohlfeld T, Braun M, Strobach H, Schrör K. Protection of reperfused ischemic pig myocardium by nexopamil, a new combined Ca2+ and serotonin antagonist. J Cardiovasc Pharmacol. 1994 Jun;23(6):922-31. PubMed PMID: 7523784. 6: Kirchengast M, Rübsamen K, Lehmann HD. Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94. PubMed PMID: 7506319.